Anti-Candida sp. (CAND-0869)
Anti-Candida sp. (CAND-0869)
Product No.: C012
- -
- -
Clone CAND-0869 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Isotype Rabbit IgG1 Applications ELISA , IHC , IFA |
- -
- -
Antibody DetailsProduct DetailsReactivity Species Candida sp. Host Species Rabbit Product Concentration ≥1.0 mg/ml Purity ≥90% Formulation Formulated in 0.01 M phosphate buffered saline, pH 7.2 and contains 0.1% sodium azide. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation This monoclonal antibody is purified by protein A chromatography or sequential differential precipitations. Storage and Handling This purified antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Applications and Recommended Usage? Quality Tested by Leinco ELISA: 1:20-1:200, IFA: 1:10-1:50 Additional Applications Reported In Literature ? IHC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity Anti-Candida (Clone CAND-0869) is specific for several Candida species: C. albicans (10 strains), C. parapsillosis, C. glabrata, C. tropicales & C. auris. It is not reactive with C. krusei, Aspergillus, Coccidioides, Histoplasma, Blastomyces, Paracoccidioides, Penicillium notatum, Mucor, Saccharomyces cerevisiae, and Pichia pastoris. Matched Pair CAND-0869 pairs with itself in ELISA Background Candida species are opportunistic fungal pathogens commonly associated with healthcare-associated infections (HAIs), particularly in immunocompromised and critically ill patients. Candida infections, also known as candidiasis or yeast infections, can manifest as a variety of clinical syndromes, including bloodstream infections, urinary tract infections, surgical site infections, and candidemia. The most frequently isolated species in the context of HAIs are Candida albicans, followed by non-albicans species like Candida glabrata, Candida parapsilosis, and Candida tropicalis. Risk factors for Candida HAIs include the use of broad-spectrum antibiotics, central venous catheterization, prolonged hospitalization, and immunosuppressive therapies. Candida species have the ability to form biofilms on medical devices, further complicating treatment and facilitating their persistence in healthcare environments. Due to the rising incidence of multidrug-resistant Candida strains, early diagnosis, appropriate antifungal therapy, and infection control measures are critical to effectively manage Candida-related HAIs and improve patient outcomes. Antigen DetailsResearch Area Fungal . Infectious Disease . Matched Pair . Nosocomial . IVD Raw Material References & CitationsTechnical Protocols |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.